Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Other Non-Current Liabilities (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Other Non-Current Liabilities for 9 consecutive years, with $4.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Liabilities rose 6.07% year-over-year to $4.3 million, compared with a TTM value of $4.3 million through Sep 2025, up 6.07%, and an annual FY2024 reading of $4.1 million, up 5.7% over the prior year.
  • Other Non-Current Liabilities was $4.3 million for Q3 2025 at CytomX Therapeutics, up from $4.2 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $4.3 million in Q3 2025 and bottomed at $216000.0 in Q2 2023.
  • Average Other Non-Current Liabilities over 3 years is $3.6 million, with a median of $4.0 million recorded in 2024.
  • Peak annual rise in Other Non-Current Liabilities hit 1748.61% in 2024, while the deepest fall reached 5.7% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $3.9 million in 2023, then rose by 5.7% to $4.1 million in 2024, then increased by 4.47% to $4.3 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for CTMX at $4.3 million in Q3 2025, $4.2 million in Q2 2025, and $4.2 million in Q1 2025.